Targeted human serum albumin nano antibody and application thereof
By targeting the fusion expression of human serum albumin nano-antibody and therapeutic protein or polypeptide drugs, the limitations of prolonging the half-life of protein drugs in the prior art are solved, and a long-term effect of high efficiency, safety and low cost are achieved.
CN119708221AActive Publication Date: 2025-03-28CHANGCHUN INST OF BIOLOGICAL PRODS
6 Cites 1 Cited by
Patent Information
- Application Number
- CN202510228082.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-02-28
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2045-02-28
AI Technical Summary
Technical Problem
The prior art has limitations in extending the half-life of protein drugs. For example, the construction of mutants requires sufficient analysis of the protein structure, high glycosylation modification costs, polyethylene glycol modification may lead to toxicity, large molecular weight of Fc/HSA fusion protein and poor tissue permeability.
Method used
By developing nano-antibody targeting human serum albumin, consisting only of heavy chain variable regions and fused with therapeutic protein or polypeptide drugs in the E. coli expression system, high specific binding to HSA and prolong drug half-life.
Benefits of technology
It achieves a complex process of structural modification of proteins or introduction of non-natural amino acids while retaining therapeutic activity.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses a targeted human serum albumin nano antibody and application thereof. The invention discloses a plurality of targeted human serum albumin nano antibodies capable of being used for constructing long-acting fusion protein drugs and an immune screening method thereof. The antibody is only composed of a heavy chain variable region and can be subjected to fusion expression with interleukin, interferon, tumor necrosis factors and other therapeutic proteins or polypeptide drugs in an escherichia coli expression system, the fusion protein has the activity of specific binding with human serum albumin, the affinity is high, the half-life period of the drugs can be effectively prolonged, and the anti-tumor effect is good. Meanwhile, the biological activity of the recombinant protein medicine is not influenced.
Need to check novelty before this filing date? Find Prior Art